VOR Vor Biopharma

Vor Bio to Participate in Upcoming Investor Conferences

Vor Bio to Participate in Upcoming Investor Conferences

BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in the following upcoming investor conferences:

TD Cowen Virtual Immunology & Inflammation Summit

Fireside Chat: Wednesday, November 12, 2025, at 2:30pm ET

8th Annual Evercore Healthcare Conference

Fireside Chat: Tuesday, December 2, 2025, 3:00pm ET

Location: Miami, FL

A live webcast and archived replay of the fireside chats will be available on the investors section of .

About Vor Bio

Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit .

Media & Investor Contacts:

Carl Mauch

 

Sarah Spencer



EN
07/11/2025

Underlying

VORVor Biopharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vor Biopharma

 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stag...

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction in proteinuria, with a favorable safety profile Telitacicept demonstrated a 55% reduction in 24-hour urine protein-to-creatinine ratio (24h-UPCR) at 39 weeks compared with placebo; statistically significant benefits also achieved across all key secondary endpoints Data presented as late-breaking oral presentation at American Society of N...

November 8, 2025 1 EN
 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Vor Bio to Participate in Upcoming Investor Conferences

Vor Bio to Participate in Upcoming Investor Conferences BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in the following upcoming investor conferences: TD Cowen Virtual Immunology & Inflammation SummitFireside Chat: Wednesday, November 12, 2025, at 2:30pm ET 8th Annual Evercore Healthcare ConferenceFireside Chat: Tuesday, December 2, 2025, 3:00pm ETLocation: Miami, FL A live webcast and archived replay of the fireside chats will be availabl...

November 7, 2025 1 EN
 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer

Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Jeremy Sokolove, M.D., as Chief Medical Officer. Dr. Sokolove brings more than two decades of clinical and translational experience in rheumatology and autoimmune disease research and development to the company’s leadership team. “We are thrilled to welcome Jeremy to Vor Bio,” said Jean-Paul Kress, M.D., Chief Executive Officer and Chairm...

November 3, 2025 1 EN
 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on October 15, 2025, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 113,478 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 24,319 shares of Vor Bio’s common stock to 20 newly hired employees. The foregoing stock options...

October 31, 2025 1 EN
 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Prof...

Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data Telitacicept delivered consistent quality-of-life improvement across both treatment and placebo crossover arms 100% of patients on telitacicept for 48 weeks achieved ≥2-point Myasthenia Gravis Activities of Daily Living (MG-ADL) improvement, with a mean reduction of -7.5 points Sustained efficacy and favorable safety extension data support potential global best-in-disease profile in generalized myasthenia gravis (gMG) BOSTON, Oct. 29,...

October 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch